Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study

BACKGROUND: This double-blind, parallel-group, multicenter, phase-3 study was designed to test the noninferiority of paliperidone palmitate 3-month formulation (PP3M) to the currently marketed 1-month formulation (PP1M) in patients (age 18–70 years) with schizophrenia, previously stabilized on PP1M....

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Int J Neuropsychopharmacol
Autors principals: Savitz, Adam J., Xu, Haiyan, Gopal, Srihari, Nuamah, Isaac, Ravenstijn, Paulien, Janik, Adam, Schotte, Alain, Hough, David, Fleischhacker, Wolfgang W.
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2016
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4966278/
https://ncbi.nlm.nih.gov/pubmed/26902950
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ijnp/pyw018
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars